Pharmacoepidemiol Risk Manage.
2024 Mar;16(1):1-10. 10.56142/perm.24.0003.
Current Issues and Improvement Strategies for Promoting the Utilization of National Health Insurance Claims Data
- Affiliations
-
- 1Department of Health Convergence, College of Science and Industry Convergence, Ewha Womans University, Seoul, Korea
- 2Department of Information and Statistics, Research Institute of Natural Science, Gyeongsang National University, Jinju, Korea
- 3College of Pharmacy, Ewha Womans University, Seoul, Korea
- 4Graduate School of Industrial Pharmaceutical Science, College of Pharmacy, Ewha Womans University, Seoul, Korea
- 5Medical Research Collaborating Center, Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea
- 6Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
- 7Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea
- 8School of Pharmacy, Sungkyunkwan University, Suwon, Korea
- 9College of Pharmacy, Chungnam National University, Daejeon, Korea
- 10College of Pharmacy, Daegu Catholic University, Gyeongsan, Korea
- 11College of Pharmacy, Chung-Ang University, Seoul, Korea
- KMID: 2556387
- DOI: http://doi.org/10.56142/perm.24.0003
Abstract
- While health insurance claims data in Korea have the potential as evidence for drug regulatory decision-making, its effective utilization remains limited. This study aims to identify the challenges encountered by researchers in utilizing claims data and discuss improvement strategies. We summarized practical difficulties encountered by researchers who have experience using claims data from the National Health Insurance Service and the Health Insurance Review and Assessment Service. Challenges encountered by researchers included difficulties in acquiring drug data, delays in data provision, limited provision of information on specific conditions, drugs, and treatments, small data capacity, short data usage periods, and spatiotemporal considerations when accessing data. To maximize the utility of claims data in drug regulatory decision-making, continuous communication between researchers and data providers is necessary for addressing these challenges.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Sensitivity of Medical Insurance Claims Data Using Population-based Cancer Registry Data
- A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples
- Physicians’ perception of the reform of the review and assessment system of national health insurance reimbursement claims
- Clinical Study Using Healthcare Claims Database
- Towards Actualizing the Value Potential of Korea Health Insurance Review and Assessment (HIRA) Data as a Resource for Health Research: Strengths, Limitations, Applications, and Strategies for Optimal Use of HIRA Data
